Answers are grounded in this paper and cite their sources.
Intravaginal RF reduced the clinical symptoms of GSM in most patients, especially during T1, and women reported satisfaction with treatment. The technique showed no adverse effects, and there were positive effects on sexual and urinary function. Trial registration This research was registered at clinicaltrial.gov (NCT03506594) and complete registration date was posted on April 24, 2018.
No takes yet. Share an insight, caveat, or question.
Pinheiro et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: